<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TRAMADOL HYDROCHLORIDE</span><br/>(tra'ma-dol)<br/><span class="topboxtradename">Ultram, </span><span class="topboxtradename">Zydol <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">analgesic</span>; <span class="classification">narcotic (opiate) agonist</span><br/><b>Prototype: </b>Morphine sulfate<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg tablets; 50 mg orally disintegrating tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Centrally acting opiate receptor agonist that inhibits the uptake of norepinephrine and serotonin, suggesting both opioid
         and nonopioid mechanisms of pain relief. May produce opioid-like effects, but causes less respiratory depression than morphine.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective agent for control of moderate to moderately severe pain.</p>
<h1><a name="uses">Uses</a></h1>
<p>Management of moderate to moderately severe pain.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to tramadol or other opioid analgesics; patients on MAO inhibitors; patients acutely intoxicated with alcohol,
         hypnotics, centrally acting analgesics, opioids, or psychotropic drugs; substance abuse; patients on obstetric preoperative
         medication; abrupt discontinuation; alcohol intoxication; pregnancy (category C); lactation; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Debilitated patients; chronic respiratory disorders; respiratory depression; older adults; liver disease; renal impairment;
         myxedema, hypothyroidism, or hypoadrenalism; GI disease; acute abdominal conditions; increased ICP or head injury, increased
         intracranial pressure; history of seizures; patients &gt;75 y.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Pain</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50100 mg q46h prn (max: 400 mg/d), may start with 25 mg/d if not well tolerated, and increase by 25 mg q3d up
               to 200 mg/d<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 50100 mg q46h prn (max: 300 mg/d), may start with 25 mg/d if not well tolerated, and increase by 25 mg q3d up
               to 200 mg/d<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <br/><span class="impairmenttitle">Hepatic Impairment</span><br/>Cirrhosis decrease to 50100 mg q12h<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li> 				Note: Dosage reduction is recommended for patients with renal insufficiency and hepatic impairment. 			</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Drowsiness, <span class="speceff-common">dizziness, vertigo, fatigue, headache, somnolence,</span> restlessness, euphoria, confusion, anxiety, coordination disturbance, sleep disturbances, seizures. <span class="typehead">CV:</span> Palpitations, vasodilation. <span class="typehead">GI:</span> <span class="speceff-common">Nausea, constipation,</span> vomiting, xerostomia, dyspepsia, diarrhea, abdominal pain, anorexia, flatulence. <span class="typehead">Body as a Whole:</span> Sweating, <span class="speceff-life">anaphylactic reaction</span> (even with first dose), withdrawal syndrome (anxiety, sweating, nausea, tremors, diarrhea, piloerection, panic attacks, paresthesia,
      hallucinations) with abrupt discontinuation.  <span class="typehead">Skin:</span> Rash. <span class="typehead">Special Senses:</span> Visual disturbances. <span class="typehead">Urogenital:</span> Urinary retention/frequency, menopausal symptoms. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Increased <span class="alt">creatinine,</span> <span class="alt">liver enzymes;</span> decreased <span class="alt">hemoglobin;</span> <span class="alt">proteinuria.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Carbamazepine</b> significantly decreases tramadol levels (may need up to twice usual dose). Tramadol may increase adverse effects of <span class="classification">mao inhibitors</span>. <span class="classification">tricyclic antidepressants</span>, <b>cyclobenzaprine,</b> <span class="classification">phenothiazines</span>, <span class="classification">selective serotonin-reuptake inhibitors (ssri</span>s), <span class="classification">mao inhibitors</span> may enhance seizure risk with tramadol. May increase CNS adverse effects when used with other <span class="classification">cns depressants</span>. <span class="typehead">Herbal:</span> <b>St. John's wort</b> may increase sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract; 75% reaches systemic circulation. <span class="typehead">Onset:</span> 3060 min. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Duration:</span> 37 h. <span class="typehead">Distribution:</span> Approximately 20% bound to plasma proteins; probably crosses bloodbrain barrier; crosses placenta; 0.1% excreted
      into breast milk. <span class="typehead">Metabolism:</span> Metabolized extensively in liver by cytochrome P450 system. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 67 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess for level of pain relief and administer prn dose as needed but not to exceed the recommended total daily dose.</li>
<li>Monitor vital signs and assess for orthostatic hypotension or signs of CNS depression.</li>
<li>Discontinue drug and notify physician if S&amp;S of hypersensitivity occur.</li>
<li>Assess bowel and bladder function; report urinary frequency or retention.</li>
<li>Use seizure precautions for patients who have a history of seizures or who are concurrently using drugs that lower the seizure
            threshold.
         </li>
<li>Monitor ambulation and take appropriate safety precautions.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Exercise caution with potentially hazardous activities until response to drug is known.</li>
<li>Understand potential adverse effects and report problems with bowel and bladder function, CNS impairment, and any other bothersome
            adverse effects to physician.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>